Key result
Imatinib inhibited PDGF-mediated proteoglycan synthesis in human vascular smooth muscle cells by 31% (P<0.01) and reduced total aortic lipid staining area in ApoE(-/-) mice by 31% (P<0.05).
p-value: p=<0.01
No takes yet. Share an insight, caveat, or question.
No clinical role for imatinib in atherosclerosis yet; leaves open PDGF inhibition as a research target in vascular disease.
Ballinger et al. (2009) studied Atherosclerosis. Imatinib vs. PDGF treatment alone / control was evaluated on PDGF-mediated (35)S-SO(4) incorporation into proteoglycans (in vitro) and total lipid staining area (in vivo) (p=<0.01). Imatinib inhibited PDGF-mediated proteoglycan synthesis in human vascular smooth muscle cells by 31% (P<0.01) and reduced total aortic lipid staining area in ApoE(-/-) mice by 31% (P<0.05).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: